RAS Polymorphisms and Systolic Dysfunction in HCM
which can affect both LV hypertrophy and remodeling. 11 It is also intriguing to speculate whether the severity of LV hypertrophy (LVH) itself can be associated with development of LV dysfunction. 4-6 Therefore, the aim of this study was to examine the potential relationship between RAS polymorphisms and development of systolic dysfunction in HCM patients based on a molecular genetic diagnosis.
Methods

Study Population
This study included 49 unrelated patients with HCM exhibiting disease-causing mutations in genes such the beta-myosin heavy chain (MYH7), cardiac myosin binding protein-C (MYBPC3), cardiac troponin T (TNNT2), and cardiac troponin I (TNNI3). In addition, their family members were clinically and genetically examined and 77 carriers with the same etiological sarcomere gene mutation as each patient were identified. Thus, total 126 genetically-affected patients (64 males, mean age 51±21 years) comprised the study population. All patients were identified at the Kanazawa University Hospital or its affiliated hospitals between 1998 and 2006.
The diagnosis of HCM was based on echocardiographic findings, such as maximal LV wall thickness ≥13 mm and the absence of any other cause of LVH as specified in the criteria of Maron et al. 12 Patients with systolic dysfunction were also included in this study: patients with (1) progression from typical HCM to systolic dysfunction during follow-up, and (2) typical HCM with an identical sarcomere gene mutation identified in the same family without any other cause of systolic dysfunction. To further examine whether hypertrophy itself can be a risk factor for developing LV dysfunction, the changes in the echocardiographic parameters from initial to last evaluation divided by follow-up period were additionally adopted as a sub-analysis. Written informed consent was given by all patients in accordance with the guidelines of the Bioethical Committee on Medical Research, School of Medicine, Kanazawa University, Kanazawa, Japan.
Genetic Studies
Genomic DNA was purified from patients' white blood cells, after which in vitro gene amplification was performed by polymerase chain reaction (PCR). Oligonucleotide primers were used to amplify all exons and exon/intron boundaries of 4 sarcomere genes, namely, MYH7, MYBPC3, TNNT2, and TNNI3, using standard protocols, as described previously. [13] [14] [15] [16] Single-strand conformational polymorphism analysis of amplified DNA was then performed. For abnormal single-strand conformational polymorphism patterns, the nucleotide sequences of the cloned PCR products were determined on both strands (bidirectional sequencing) by the dye terminator cycle sequencing method using an automated fluorescent sequencer (ABI PRISM TM 310 Genetic Analyzer, PE Biosystems, Foster City, CA, USA). The sequence variation was confirmed by restriction enzyme digestion.
Determination of RAS-Related Gene Polymorphisms
In this study, we chose the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) and the angiotensin II type 1 receptor (AT1-R) A/C 1166 from among the many RAS polymorphisms because these 2 polymorphisms (ie, the ACE D allele (DD and ID genotypes) and the AT1-R C 1166 allele (CC and AC genotypes)) are reported to be associated with increased LVH in HCM. [17] [18] [19] Gene polymorphisms of ACE I/D were identified by PCR performed with a set of oligonu-cleotide primers flanking the polymorphic site in intron 16. To avoid mistyping, each sample found to have the DD genotype was subjected to a second round of independent PCR amplification with a primer pair that recognized an insertionspecific sequence, as described previously. 20 The AT1-R A/ C 1166 polymorphism was determined by PCR and restriction fragment length polymorphisms, as previously reported. 21 PCR was performed to amplify a fragment encompassing the polymorphic site at nucleotide position 1166 in the 3' untranslated region of the human AT1-R gene. PCR products were then digested with restriction enzyme DdeI (Toyobo, Osaka, Japan) and the cleaved products were separated by electrophoresis.
Echocardiographic Examinations
Standard transthoracic M-mode and 2-dimensional echocardiographic studies were performed to identify and quantify the morphologic features of the LV. LV end-diastolic dimension (LVDd) and end-systolic dimension (LVDs), and the thicknesses of the interventricular septum (IVST) and LV posterior wall (PWT) were measured at the level of the tips of the mitral valve leaflets. Additionally, we measured the anterior and lateral walls of the LV at the same levels used for measuring the septum and posterior walls. From these measurements, we defined the maximal LV wall thickness (MWT). Ejection fraction (EF) was calculated by Teichholz's method and by modified Simpson's method when LV dilatation or regional decrease of LV wall motion occurred. The left atrial dimension was measured at end-systole.
Statistical Analysis
Values are expressed as mean ± SD. Measured values were compared between 2 groups with an unpaired Student's ttest. Comparison between groups was performed using a one-way analysis of variance followed by Scheffé's method. Categorical variables were compared by the chi-square test for independence. A P-value <0.05 was considered statistically significant. Statistical analyses were carried out with the computer software StatView for Windows version 5.0 (Abacus Concepts, Inc, Berkeley, CA, USA).
Results
Genetic Results and Clinical Characteristics of the Study Population
The demographic and clinical characteristics of the study population are presented in Table 1 ; 15 different mutations were identified in 126 patients and among them, 17 patients had mutations in MYH7 (Ala26Val, n=4; Arg204His, n=1; Arg858Cys, n=4; Arg870Cys, n=1; Gly733Glu, n=2; Met822Leu, n=2; and Glu935Lys, n=3), 35 patients had mutations in MYBPC3 (Arg820Gln, n=15; c.2067+1G>A, n=15; and Del593C, n=5), 23 patients had mutations in TNNT2 (Arg92Trp, n=10; Lys273Glu, n=10; Val85Leu, n=1; and Phe110Ile, n=2), and 51 patients had a mutation in TNNI3 (Lys183Del; n=51). All of these mutations have been identified and described elsewhere. 22, 23 As for the frequencies of ACE I/D, 36% were II, 44% were ID and 20% were DD. For the AT1-R A/C 1166 , 89% were AA and 11% were AC (Table 1); 9 of the 126 patients had both the ACE D and AT1-R C 1166 alleles and of these 9 patients 7 were from 7 unrelated kindred with genetic mutations (MYH7=1, MYBPC3=1, TNNT2=1 and TNNI3=4), and the other 2 were from a kindred with a TNNT2 mutation in which 1 was typical HCM and the other had systolic dysfunction.
The differences in the underlying sarcomere gene mutations are shown in Table 2 . There were no differences between the 4 genes with respect to echocardiographic parameters. Regarding the relationship between sarcomere gene mutations and RAS polymorphisms, the proportion of the II genotype of ACE I/D polymorphisms was higher than that of the D allele only in association with MYBPC3 mutation ( Table 2) .
Echocardiographic Parameters and RAS Polymorphisms
Among the ACE I/D polymorphisms, the presence of the dominant D allele (DD and ID genotypes) was associated with significantly decreased PWT (10±2 mm vs 11±3 mm, P<0.05), larger LVDs (32±11 mm vs 28±7 mm, P<0.05) and lower EF (56±15% vs 62±12%, P<0.05) than in those with the II genotype. We demonstrate 2 representative patients who showed entirely different clinical manifestations, despite having an identical mutation of Arg92Trp in TNNT2. 24 One had dilated cardiomyopathy-like features with the ACE D Values are mean ± SD unless otherwise shown. Abbreviations as in Table 1 . RAS Polymorphisms and Systolic Dysfunction in HCM allele and the other with an ACE II genotype had typical HCM (Figure) . Interestingly, the presence of the ACE D allele with the AT1-R C 1166 allele was associated with significantly larger LVDs (37±17 mm vs 30±9 mm, P<0.05) and lower EF (48±20% vs 58±14%, P<0.05) compared with others ( Table 3) , although AT1-R A/C 1166 polymorphism itself did not influence the echocardiographic parameters. When patients were divided into 3 groups, such as ACE D allele with AT1-R C 1166 allele (n=9), ACE D allele with AT1-R AA 1166 genotype (n=72) and ACE II genotype with AT1-R C 1166 allele or AT1-R AA 1166 genotype (n=45), those with the ACE D and AT1-R C 1166 alleles showed the largest LVDs dimension (37±17 mm vs 31±10 mm vs 28±7 mm, P<0.05) and the lowest EF (48±20% vs 56±14% vs 62±12%, P<0.05) among the 3 groups.
Effect of LVH on the Relationship Between LV Dysfunction and RAS Polymorphisms
To study the development of LV dysfunction, 59 of the 126 patients underwent serial echocardiography at least 2 years apart. After excluding 15 patients with LV dysfunction such as EF <50% and/or LVDd >55 mm at initial evaluation, the data from the remaining 44 patients (25 males, mean age 48±16 years and mean follow-up 6.7±3.5 years) were analyzed. When patients were divided into 2 groups by median MWT of 19 mm, there were 23 patients with MWT ≥19 mm and 21 patients with MWT <19 mm. There was no significant difference between the 2 groups in the frequencies of diseasecausing genes and RAS polymorphisms. Interestingly, MWT and IVST decreased by 0.46±1.01 and 0.35±1.14 mm/year, respectively, in patients with MWT ≥19 mm, although MWT and IVST increased by 0.43±0.78 and 0.43±0.75 mm/year, respectively, in those with MWT <19 mm (P<0.05, respec- Table 4) . Thus, patients with MWT ≥19 mm showed higher annual EF decrease and larger annual LV dimension increase than patients with MWT <19 mm, although results did not reach statistical significance.
Discussion
The major findings of this study are that, in addition to severity of LVH, the ACE D allele is associated with develop-ment of systolic dysfunction and LV dilatation in genotyped HCM. Furthermore, the presence of the ACE D allele with the AT1-R C 1166 allele appears to be a risk factor for further systolic dysfunction and LV dilatation.
The ACE D allele has been reported to be associated with higher plasma ACE levels than the II genotype, 25 and subjects with the AT1-R C 1166 allele exhibit higher angiotensin II responses than those with the AA genotype. 26 Therefore, the ACE D and AT1-R C 1166 alleles cause an increase in RAS Values are mean ± SD. ACE D with AT1-R C = ACE D allele with AT1-R C allele; other abbreviations as in Table 1 . Values are mean ± SD unless otherwise shown. Δ, change from initial evaluation to last evaluation. All abbreviations as in Table 1 . RAS Polymorphisms and Systolic Dysfunction in HCM activity, which is closely related to myocardial hypertrophy and subsequent LV remodeling. 11 Indeed, the ACE D and the AT1-R C 1166 alleles have been reported as associated with increased LVH in HCM. [17] [18] [19] In previous follow-up studies of the predictors of LV systolic dysfunction in HCM, patients who developed systolic dysfunction had a greater LV wall thickness than patients who maintained normal systolic function at initial evaluation. 4-6 Thus, it is possible that these 2 RAS polymorphisms are associated not only with LVH but also with subsequent LV remodeling that can lead to development of systolic dysfunction and LV dilatation. However, few data exist regarding the relationship between these polymorphisms and the progression of systolic dysfunction in HCM patients because of methodological difficulties in collecting both phenotypic and genetic data from such cases.
In the present study, the ACE D allele was associated with decreased PWT, decreased EF and increased LVDs. In addition, the presence of the ACE D allele with the AT1-R C 1166 allele was associated with further decrease in EF and increase in LVDs, both of which reflect LV remodeling. Therefore, one might speculate that the ACE D and AT1-R C 1166 alleles are responsible for LVH and subsequent LV remodeling. The present study is the first to demonstrate the novel modifying effects of these RAS polymorphisms as a risk factor for progression of systolic dysfunction and LV dilatation in the clinical setting. RAS polymorphisms partially account for the inter-and intrafamilial variability in the phenotypic expression of HCM.
It was quite interesting that the combination of the ACE D and AT1-R C 1166 alleles contributed to the development of systolic dysfunction and LV dilatation. The ACE I/D and AT1-R A/C 1166 polymorphisms are known as those that cause LVH. Indeed, studies have revealed a direct relationship between the burden of polymorphisms and the degree of LVH in HCM. 8, 9 In a histologic study, the burden of gene polymorphisms related to LVH was associated with the extent of cardiomyocyte hypertrophy in HCM. 27 Those results support the hypothesis of different polymorphic genotypes forming a compound unit, the components of which act in a related manner. 8 In the present study, the presence of the ACE D and AT1-R C 1166 alleles was associated with further decrease in EF and increase in LVDs compared with the ACE D allele alone. It is possible that the combined effects of polymorphisms related to LVH are associated with not only LVH but also the resultant further LV remodeling that can lead to greater systolic dysfunction and LV dilatation.
In contrast to the results of previous studies, 17-19 neither the ACE D nor the AT1-R C 1166 allele itself was related to the presence of LVH in the present study. This may be explained by the fact that almost all of the previous studies had limited numbers of patients and the inclusion criteria differed from ours. In particular, the patients enrolled in previous studies were diagnosed as HCM only by echocardiography without the genetic analysis that was an important part of the inclusion criteria for the present study. Inclusion of HCM with systolic dysfunction in the present study might also have contributed to the different results. Indeed, 25 of the 126 (20%) patients has decreased EF (<50%). The AT1-R CC 1166 genotype was not found in the present study, probably because of the small number of patients with the AT1-R CC 1166 genotype in the general Japanese population. 21 During the follow-up, MWT and IVST in patients with MWT ≥19 mm decreased, although those in patients with MWT <19 mm increased, which suggests that LV remodeling is prominent in accordance with LVH. Indeed, patients with MWT ≥19 mm showed higher annual EF decreases and larger annual LV dimension increases than patients with MWT <19 mm. Under these conditions, RAS polymorphisms were not associated with LVH and development of LV dysfunction, probably because we excluded patients with LV dysfunction at initial evaluation, as they could be highly affected by RAS. It is also possible that LV dysfunction because of hypertrophy reflects remodeling caused by ischemia, myocardial fibrosis, small vessel disease and myocardial disarray, suggesting that other genetic or environmental factors could be involved. 5,6
Clinical Implications and Study Limitations
It has been recently demonstrated that angiotensin II type 1 receptor blockers decreased myocardial fibrosis in a transgenic mouse model of human HCM, 28 and this class of drug has improved LV diastolic function and prevented progression of LVH in clinical HCM patients. 29, 30 In the present study, the presence of the ACE D and AT1-R C 1166 alleles was shown to be a possible maker for effective prediction of systolic dysfunction and LV dilatation in HCM. For pharmacological intervention, we suggest that RAS blockade could be effective in patients with these RAS polymorphisms, although the rationale and hypothesis need further investigation.
There remain several limitations to the present study. First, we did not include all of the disease-causing genes, only screening for the 4 major disease-causing genes because their frequencies are higher than the others and comprise most of the genotyped HCM cases, even in the Japanese HCM population. 22,31 Second, 51 of the 126 (40%) genetically-affected patients had a mutation in TNNI3, which has caused less than 6% of HCM in most large series studied to date. Therefore, the distribution of mutations in our population was somewhat different from those previously reported. 22, 31 Third, we studied only 2 gene polymorphisms related to LVH: ACE I/D and AT1-R A/C 1166 . Therefore, further investigation of the other polymorphisms related to LVH, such as angiotensinogen M235T, an A/G exchange at position-1903 of the cardiac chymase A gene, and a C/T exchange at position-344 in the aldosterone synthase gene, is necessary in future to confirm the association between RAS polymorphisms and the development of systolic dysfunction. 8, 9, 27 Fourth, there may be familial bias, because gene-specific genotype-phenotype correlations have been reported. 24,32,33 However phenotypic variability of HCM is not completely explained by disease-causing gene mutation alone. 8-10 From that we infer that the final phenotype is likely the consequence of interaction between the disease-causing gene mutation and other gene variants in the genetic background, such as RAS polymorphisms and environmental factors.
Finally, a proportion of the original study population did not undergo serial evaluation. Therefore, we could not precisely demonstrate a relationship between RAS polymorphisms and life-long LV remodeling from hypertrophy to dysfunction. However, it can be speculated that LV dysfunction would be more prominent in patients with previously greater LV wall thickness and this process would be modified by RAS polymorphisms, as shown in the present study. Long-term follow-up of a large number of patients may confirm this hypothesis.
Conclusions
The ACE D allele is associated with systolic dysfunction and LV dilatation in genotyped HCM. Furthermore, the pres-FUNADA A et al.
ence of the ACE D and AT1-R C 1166 alleles is closely related to further systolic dysfunction and LV dilatation, although LVH itself may contribute to the development of LV dysfunction. We suggest that, in addition to screening for disease-causing gene mutations, detection of these RAS polymorphisms may assist further risk stratification and better pharmacological therapy in genotyped HCM patients.
